MRKMerck Sharp & Dohme LLCRunning, no new patients
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Non-small Cell Lung Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 797 (final count)
- Started
- Apr 24, 2018
- Main results expected
- Jul 10, 2023
- Fully finished
- Oct 15, 2026
- Results posted
- Sep 19, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event Free Survival (EFS)
Measured over: Up to approximately 5 years
Overall Survival (OS)
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03425643 · record last updated 2026-07-29 · checked 2026-11-09 15:47 UTC